



US009408850B2

(12) **United States Patent**  
**Lombardi Borgia et al.**

(10) **Patent No.:** **US 9,408,850 B2**  
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **SUBSTITUTED INDAZOLE DERIVATIVES**  
**ACTIVE AS KINASE INHIBITORS**

(75) Inventors: **Andrea Lombardi Borgia**, Paullo (IT);  
**Marina Ciomei**, Corsico (IT); **Daniele**  
**Donati**, Nerviano (IT); **Marcella Nesi**,  
Saronno (IT)

(73) Assignee: **NERVIANO MEDICAL SCIENCES**  
**S.R.L.**, Nerviano (MI) (IT)

(\* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 133 days.

(21) Appl. No.: **14/116,512**

(22) PCT Filed: **May 7, 2012**

(86) PCT No.: **PCT/EP2012/058389**

§ 371 (c)(1),  
(2), (4) Date: **Nov. 8, 2013**

(87) PCT Pub. No.: **WO2012/152763**

PCT Pub. Date: **Nov. 15, 2012**

(65) **Prior Publication Data**

US 2014/0080807 A1 Mar. 20, 2014

(30) **Foreign Application Priority Data**

May 12, 2011 (EP) ..... 11165882

(51) **Int. Cl.**

**C07D 231/56** (2006.01)  
**C07D 401/12** (2006.01)  
**C07D 295/185** (2006.01)  
**C07D 405/12** (2006.01)  
**C07D 403/12** (2006.01)  
**A61K 31/496** (2006.01)  
**A61K 31/416** (2006.01)  
**A61K 31/5377** (2006.01)  
**C07D 401/14** (2006.01)  
**C07D 403/14** (2006.01)  
**A61K 31/454** (2006.01)  
**A61K 45/06** (2006.01)  
**C07D 295/155** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/5377** (2013.01); **A61K 31/416**  
(2013.01); **A61K 31/454** (2013.01); **A61K**  
**31/496** (2013.01); **A61K 45/06** (2013.01);  
**C07D 231/56** (2013.01); **C07D 295/155**  
(2013.01); **C07D 295/185** (2013.01); **C07D**  
**401/12** (2013.01); **C07D 401/14** (2013.01);  
**C07D 403/12** (2013.01); **C07D 403/14**  
(2013.01); **C07D 405/12** (2013.01)

(58) **Field of Classification Search**

None  
See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO WO 03/028720 A1 4/2003  
WO WO 2005/073224 A2 8/2005  
WO WO 2005/085206 A1 9/2005  
WO WO 2008/003396 A1 1/2008  
WO WO 2010/069966 A1 6/2010

OTHER PUBLICATIONS

Antonescu C.R., "The GIST Paradigm: Lessons for Other Kinase-Driven Cancers", *Journal of Pathology* 223:251-261 (2011).  
Cohen P., "The Development and Therapeutic Potential of Protein Kinase Inhibitors", *Current Opinion in Chemical Biology* 3:459-465 (1999).  
Cohen P., "Protein Kinases—The Major Drug Targets of the Twenty-First Century?", *Nature Reviews—Drug Discovery* 1:309-315 (Apr. 2002).  
Colombo M. et al., "A Fully Automated Method for Accurate Mass Determination Using High-Performance Liquid Chromatography with a Quadrupole/Orthogonal Acceleration Time-of-Flight Mass Spectrometer", *Rapid Communications in Mass Spectrometry* 18:511-517 (2004).  
Curtin J.A. et al., "Somatic Activation of KIT in Distinct Subtypes of Melanoma", *Journal of Clinical Oncology* 24(26):4340-4346 (Sep. 10, 2006).  
Horiike S. et al., "Tandem Duplications of the FLT3 Receptor Gene are Associated with Leukemic Transformation of Myelodysplasia", *Leukemia* 11:1442-1446 (1997).  
Hunter T., "Signaling-2000 and Beyond", *Cell* 100:113-127 (Jan. 7, 2000).  
Lim K-H et al., "KIT and Mastocytosis", *Acta Haematol* 119:194-198 (2008).  
Malaise M. et al., "Clinical Implications of C-Kit Mutations in Acute Myelogenous Leukemia", *Current Hematologic Malignancy Reports* 4:77-82 (2009).  
Masson K. et al., "Oncogenic Signaling from the Hematopoietic Growth Factor Receptors C-Kit and Flt3", *Cellular Signalling* 21:1717-1726 (2009).  
Micke P. et al., "Characterization of C-Kit Expression in Small Cell Lung Cancer: Prognostic and Therapeutic Implications", *Clinical Cancer Research* 9:188-194 (Jan. 2003).  
Morris P.G. et al., "Novel Targeted Agents for Platelet-Derived Growth Factor Receptor and C-Kit in Malignant Gliomas", *Targ Oncol* 5:193-200 (2010).  
Murakami T. et al., "New KIT Mutations in Patients with Piebaldism", *Journal of Dermatological Science* 35:29-33 (2004).  
Nakao M. et al., "Internal Tandem Duplication of the Flt3 Gene Found in Acute Myeloid Leukemia", *Leukemia* 10:1911-1918 (1996).

(Continued)

*Primary Examiner* — Kamal Saeed

(74) *Attorney, Agent, or Firm* — Scully, Scott, Murphy & Presser, P.C.

(57) **ABSTRACT**

The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

**6 Claims, No Drawings**